Biotechnology in the United Kingdom
| Product Code | MKL00634 |
| Publication Date | September 2011 |
| Publisher | Marketline |
| Product Type | Report |
| Pages | 40 |
| ISBN Number | not applicable |
Biotechnology in the United Kingdom
Introduction
Biotechnology in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value 2006-10, and forecast to 2015). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the United Kingdom biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
- The biotechnology market consists of the development, manufacturing and marketing of products based on advanced biotechnology research. The market value reflects revenues of companies within this industry from product sales, licensing fees, royalties and research funding. Any currency conversions used in the creation of this report have been calculated using constant 2011 annual average exchange rates.
- The UK biotechnology market had total revenue of $6,980.5 million in 2010, representing a compound annual growth rate (CAGR) of 3.6% between 2006 and 2010.
- Medical/Healthcare sales proved the most lucrative for the UK biotechnology market in 2010, with total revenues of $4,826.5 million, equivalent to 69.1% of the market's overall value.
- The performance of the market is forecast to accelerate, with an anticipated CAGR of 4% for the five-year period 2010 - 2015, which is expected to drive the market to a value of $8,503.2 million by the end of 2015.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in the United Kingdom
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in the United Kingdom
Leading company profiles reveal details of key biotechnology market players' global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the United Kingdom biotechnology market with five year forecasts
Macroeconomic indicators provide insight into general trends within the United Kingdom economy
Key Questions Answered
What was the size of the United Kingdom biotechnology market by value in 2010?
What will be the size of the United Kingdom biotechnology market in 2015?
What factors are affecting the strength of competition in the United Kingdom biotechnology market?
How has the market performed over the last five years?
What are the main segments that make up the United Kingdom's biotechnology market?
Contents
- EXECUTIVE SUMMARY
- MARKET OVERVIEW
- Market definition
- Research highlights
- Market analysis
- MARKET VALUE
- MARKET SEGMENTATION I
- MARKET SEGMENTATION II
- FIVE FORCES ANALYSIS
- Summary
- Buyer power
- Supplier power
- New entrants
- Substitutes
- Rivalry
- LEADING COMPANIES
- Astra Zeneca
- GE Healthcare
- Novartis AG
- Sanofi-Aventis Group
- MARKET FORECASTS
- Market value forecast
- MACROECONOMIC INDICATORS
- APPENDIX
- Methodology
- Industry associations
- Related Datamonitor research
- Disclaimer
- ABOUT DATAMONITOR
- Premium Reports
- Summary Reports
- Datamonitor consulting
- LIST OF TABLES
- Table 1: United Kingdom biotechnology market value: $ million, 2006-10
- Table 2: United Kingdom biotechnology market segmentation I:% share, by value, 2010
- Table 3: United Kingdom biotechnology market segmentation II: % share, by value, 2010
- Table 4: Astra Zeneca: key facts
- Table 5: Astra Zeneca: key financials ($)
- Table 6: Astra Zeneca: key financial ratios
- Table 7: GE Healthcare: key facts
- Table 8: GE Healthcare: key financials ($)
- Table 9: GE Healthcare: key financial ratios
- Table 10: Novartis AG: key facts
- Table 11: Novartis AG: key financials ($)
- Table 12: Novartis AG: key financial ratios
- Table 13: Sanofi-Aventis Group: key facts
- Table 14: Sanofi-Aventis Group: key financials ($)
- Table 15: Sanofi-Aventis Group: key financials (€)
- Table 16: Sanofi-Aventis Group: key financial ratios
- Table 17: United Kingdom biotechnology market value forecast: $ million, 2010-15
- Table 18: United Kingdom size of population (million), 2006-10
- Table 19: United Kingdom gdp (constant 2000 prices, $ billion), 2006-10
- Table 20: United Kingdom gdp (current prices, $ billion), 2006-10
- Table 21: United Kingdom inflation, 2006-10
- Table 22: United Kingdom consumer price index (absolute), 2006-10
- Table 23: United Kingdom exchange rate, 2006-10
- LIST OF FIGURES
- Figure 1: United Kingdom biotechnology market value: $ million, 2006-10
- Figure 2: United Kingdom biotechnology market segmentation I:% share, by value, 2010
- Figure 3: United Kingdom biotechnology market segmentation II: % share, by value, 2010
- Figure 4: Forces driving competition in the biotechnology market in the United Kingdom, 2010
- Figure 5: Drivers of buyer power in the biotechnology market in the United Kingdom, 2010
- Figure 6: Drivers of supplier power in the biotechnology market in the United Kingdom, 2010
- Figure 7: Factors influencing the likelihood of new entrants in the biotechnology market in the United Kingdom, 2010
- Figure 8: Factors influencing the threat of substitutes in the biotechnology market in the United Kingdom, 2010
- Figure 9: Drivers of degree of rivalry in the biotechnology market in the United Kingdom, 2010
- Figure 10: Astra Zeneca: revenues & profitability
- Figure 11: Astra Zeneca: assets & liabilities
- Figure 12: GE Healthcare: revenues & profitability
- Figure 13: GE Healthcare: assets & liabilities
- Figure 14: Novartis AG: revenues & profitability
- Figure 15: Novartis AG: assets & liabilities
- Figure 16: Sanofi-Aventis Group: revenues & profitability
- Figure 17: Sanofi-Aventis Group: assets & liabilities
- Figure 18: United Kingdom biotechnology market value forecast: $ million, 2010-15
